CY1110953T1 - Καινοτομος d3n παραλλαγη γλυκοζυλιωσης της fsh - Google Patents

Καινοτομος d3n παραλλαγη γλυκοζυλιωσης της fsh

Info

Publication number
CY1110953T1
CY1110953T1 CY20101101080T CY101101080T CY1110953T1 CY 1110953 T1 CY1110953 T1 CY 1110953T1 CY 20101101080 T CY20101101080 T CY 20101101080T CY 101101080 T CY101101080 T CY 101101080T CY 1110953 T1 CY1110953 T1 CY 1110953T1
Authority
CY
Cyprus
Prior art keywords
tracker
fsh
glycosylation
fsh glycosylation
mutated
Prior art date
Application number
CY20101101080T
Other languages
English (en)
Inventor
Marco Muda
Xuliang Jiang
Sean D Mckenna
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of CY1110953T1 publication Critical patent/CY1110953T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Περιγράφεται η μεταλλαγμένη FSH με αυξημένη γλυκοζυλίωση και μακρύτερο χρόνο ημιζωής. Η χρήση αυτής της μεταλλαγμένης FSH για την πρόκληση της ωοθυλακιογένεσης σε ανθρώπους ασθενείς περιγράφεται επίσης.
CY20101101080T 2006-01-17 2010-11-25 Καινοτομος d3n παραλλαγη γλυκοζυλιωσης της fsh CY1110953T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75948606P 2006-01-17 2006-01-17
EP07716617A EP1981908B1 (en) 2006-01-17 2007-01-16 Novel fsh glycosylation variant d3n

Publications (1)

Publication Number Publication Date
CY1110953T1 true CY1110953T1 (el) 2015-06-11

Family

ID=38163618

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101080T CY1110953T1 (el) 2006-01-17 2010-11-25 Καινοτομος d3n παραλλαγη γλυκοζυλιωσης της fsh

Country Status (22)

Country Link
US (1) US7956034B2 (el)
EP (1) EP1981908B1 (el)
JP (1) JP2009523445A (el)
KR (1) KR20080094697A (el)
CN (1) CN101370825B (el)
AR (1) AR059054A1 (el)
AT (1) ATE487738T1 (el)
AU (1) AU2007207697B2 (el)
BR (1) BRPI0706628A2 (el)
CA (1) CA2633844A1 (el)
CY (1) CY1110953T1 (el)
DE (1) DE602007010425D1 (el)
DK (1) DK1981908T3 (el)
EA (1) EA013974B1 (el)
HR (1) HRP20100610T1 (el)
IL (1) IL192547A (el)
PL (1) PL1981908T3 (el)
PT (1) PT1981908E (el)
RS (1) RS51792B (el)
SI (1) SI1981908T1 (el)
WO (1) WO2007084441A2 (el)
ZA (1) ZA200805194B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1917276B1 (en) * 2005-08-26 2018-03-21 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
AU2006323925B2 (en) * 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
BRPI0620223A2 (pt) * 2005-12-22 2011-11-01 Serono Lab mutantes de fsh
AU2008314687A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying Fc-fusion proteins
JP2011500757A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ含有タンパク質の精製方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9810478A (pt) * 1997-06-25 2000-09-12 Applied Research Systems Análogos de hormÈnio glicoproteìna reticulados por dissulfeto e sua preparação e utilização
WO2001058493A1 (en) * 2000-02-11 2001-08-16 Maxygen Aps Conjugates of follicle stimulating hormones
EP1487479B1 (en) * 2001-10-22 2012-06-20 Merck Serono SA Mutant glycoproteins
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
AU2006323925B2 (en) * 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant

Also Published As

Publication number Publication date
AU2007207697A1 (en) 2007-07-26
BRPI0706628A2 (pt) 2011-04-05
ZA200805194B (en) 2009-10-28
WO2007084441A3 (en) 2007-09-07
US20080280832A1 (en) 2008-11-13
DK1981908T3 (da) 2010-12-13
AU2007207697A2 (en) 2008-07-31
CA2633844A1 (en) 2007-07-26
IL192547A0 (en) 2009-02-11
EA200870177A1 (ru) 2009-02-27
CN101370825A (zh) 2009-02-18
PL1981908T3 (pl) 2011-04-29
AU2007207697B2 (en) 2012-01-19
EP1981908B1 (en) 2010-11-10
EP1981908A2 (en) 2008-10-22
PT1981908E (pt) 2010-11-23
KR20080094697A (ko) 2008-10-23
ATE487738T1 (de) 2010-11-15
WO2007084441A2 (en) 2007-07-26
US7956034B2 (en) 2011-06-07
HRP20100610T1 (hr) 2010-12-31
AR059054A1 (es) 2008-03-12
DE602007010425D1 (de) 2010-12-23
JP2009523445A (ja) 2009-06-25
SI1981908T1 (sl) 2011-01-31
IL192547A (en) 2012-04-30
CN101370825B (zh) 2012-10-10
RS51792B (en) 2011-12-31
EA013974B1 (ru) 2010-08-30

Similar Documents

Publication Publication Date Title
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY1121042T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
CY1118221T1 (el) Εκλεκτικοι συνδετες συνδεσης οψινης, συνθεσεις και μεθοδοι χρησης
TWD198323S (zh) 口腔保健裝置（二）
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
NO20091064L (no) Antistoffer mot IL-17A
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
CR7875A (es) Variantes de inmunoglobina y usos de esto
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
CY1115350T1 (el) Χρησεις αναστολεων της dpp iv
UA94221C2 (en) Lipocalin protein
CY1110953T1 (el) Καινοτομος d3n παραλλαγη γλυκοζυλιωσης της fsh
CL2007001665A1 (es) Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
CY1117191T1 (el) Χρηση τεστοστερονης και ενος αγωνιστικου 5-ητ1α στην θεραπεια σεξουαλικης δυσλειτουργιας
ECSP077222A (es) Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
TWD200964S (zh) 口腔保健裝置（一）
CY1115194T1 (el) Χρηση της μακρας πεντραξινης ptx3 για την προληψη ή θεραπεια ιικων ασθενειων
BRPI0809079A2 (pt) tratamento de câncer com um combinado de il-18 humana e anticorpo anti-cd20
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
CY1112121T1 (el) ΠΑΡΑΓΩΓΑ ΤΩΝ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-[1,2-α]-ΠΥΡΑΖΙΝ-6-ΚΑΡΒΟΞΑΜΙΔΙΩΝ ΚΑΙ ΤΩΝ 2,3,4,5-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-(1,2-α)-ΔΙΑΖΕΠΙΝ-7-ΚΑΡΒΟΞΑΜΙΔΙΩΝ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ
BR112013009660A2 (pt) proteína de fusão com fator de atividade ix
AR087094A1 (es) Formulaciones que estabilizan proteinas
ECSP077423A (es) Coadministración de tigeciclina y digoxin